A study from Uganda found that adolescents infected with a flatworm still mounted an immune defense when vaccinated against TB.
In the new phase II open label trial, Anne Wajja, of the MRC/UVRI Uganda Research Unit, and colleagues tested the investigational tuberculosis vaccine MVA85A on 36 healthy adolescents from Uganda who had all previously received the BCG vaccine. Half had no helminth infections and the other half were infected only with Schistosoma mansoni. The researchers measured the immune response to the vaccine in each patient and recorded any adverse events.
All patients had an immune response to the tuberculosis vaccine, with no difference between those infected with Schistosoma mansoni and those uninfected. Moreover, there were no serious adverse events during the course of the study.
Read more at www.medicalxpress.com
